MTOR and breast cancer: For example, the AMPK activator metformin has shown potential for combined application with chemotherapy or immunotherapy in clinical trials of breast cancer, colorectal cancer, and head and neck cancer; while mTOR inhibitors such as everolimus and rapamycin have been widely tested in clinical trials of multiple cancers, including breast cancer, colorectal cancer, liver cancer, and prostate cancer.